Dose-Response of Beta-Blockers in Adrenergic Receptor Polymorphism Genotypes

BACKGROUND: In HFrEF two clinical trials, the Beta-Blocker Evaluation of Survival Trial (BEST) and HF-ACTION, have reported an effectiveness interaction between the ADRB1 Arg389Gly polymorphism and beta-blockers (BBs). HF-ACTION additionally reported a dose-related interaction of unclear origin. If...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Circ Genom Precis Med
Autores principales: Parikh, Kishan S., Fiuzat, Mona, Davis, Gordon, Neely, Megan, Blain-Nelson, Penny, Whellan, David J., Abraham, William T., Adams, Kirkwood F., Felker, G. Michael, Liggett, Stephen B., O’Connor, Christopher M., Bristow, Michael R.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2018
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6205732/
https://ncbi.nlm.nih.gov/pubmed/30354340
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCGEN.117.002210
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares